ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th.

Management will host a conference call at 5:00 p.m. Eastern Time on November 12th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast , or access the teleconference . The live webcast can also be accessed via the company’s website at . The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.



Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
 

Press and Media Inquiries:
Organogenesis
EN
16/10/2024

Underlying

ORGOOrganogenesis Holdings (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Expands Manufacturing Capacity to Support Future Growth CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. “We are pleased to join the Rhode Isl...

12h / 15m 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Resul...

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Summary: Net revenue of $115.2 million for the third quarter of 2024, an increase of $6.6 million compared to net rev...

November 12, 2024 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Announces $130 Million Private Placement O...

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered in...

November 12, 2024 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clin...

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of sy...

November 11, 2024 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 202...

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th. Management will host a conference call at 5:00 p.m. Eas...

October 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch